Development of AZD-2820 obesity drug halted

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1419, 2012-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-obesity drug development

By Bays Harold Dujovne Carlos

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1189-1204

Informa Healthcare

Access to resources Recommend Favorite

Adipose targets for obesity drug development

By Boss Olivier Bergenhem Nils

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 1, 2006-02 ,pp. : 119-134

Informa Healthcare

Access to resources Recommend Favorite

Early development evaluation of AZD8081: a substrate for the NK receptors

By Sigfridsson K. Ahlqvist M. Carlsson A. Fridströöm A.

Drug Development and Industrial Pharmacy, Vol. 37, Iss. 6, 2011-06 ,pp. : 702-713

Informa Healthcare

Access to resources Recommend Favorite

Early development evaluation of AZD2738, a substrate for the NK receptors

By Sigfridsson Kalle Ahlqvist Matti Lindsjöö Martin Paulsson Stefan

Drug Development and Industrial Pharmacy, Vol. 37, Iss. 6, 2011-06 ,pp. : 719-726

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status

By Parker E. Van Heek M. Stamford A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 173-187

Elsevier

Access to resources Recommend Favorite